Jazz Pharms
Stock
Stock
ISIN: IE00B4Q5ZN47
Ticker: JAZZ
IE00B4Q5ZN47
JAZZ
Price
Price
CHART BY
Frequently asked questions
What is Jazz Pharms's market capitalization?
The market capitalization of Jazz Pharms is $7.43B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Jazz Pharms's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Jazz Pharms is 17.71. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Jazz Pharms?
Jazz Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $6.943. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Jazz Pharms's stock?
Currently, 21 analysts cover Jazz Pharms's stock, with a consensus target price of $180.72. Analyst ratings provide insights into the stock's expected performance.
What is Jazz Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Jazz Pharms reported a revenue of $3.99B.
What is the EBITDA for Jazz Pharms?
Jazz Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.39B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Jazz Pharms?
Jazz Pharms has a free cash flow of $1.13B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Jazz Pharms have, and what sector and industry does it belong to?
Jazz Pharms employs approximately 2,800 people. It operates in the Health Care sector, specifically within the Pharmaceuticals: Major industry.
What is the free float of Jazz Pharms's shares?
The free float of Jazz Pharms is 57.91M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $7.43B
- EPS (TTM)
- $6.943
- Free Float
- 57.91M
- P/E ratio (TTM)
- 17.71
- Revenue (TTM)
- $3.99B
- EBITDA (TTM)
- $1.39B
- Free Cashflow (TTM)
- $1.13B
Pricing
- 52W span
- $99.33$134.13
Analyst Ratings
The price target is $180.72 and the stock is covered by 21 analysts.
Buy
18
Hold
3
Sell
0
Information
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
- Employees
- 2,800
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- IE00B4Q5ZN47
- Primary Ticker
- JAZZ